{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:53:56Z","timestamp":1787741636337,"version":"build-2784847793"},"reference-count":29,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"3","license":[{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"vor","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>In October 2015, the Food and Drug Administration (FDA) instituted an update to the mandatory Risk Evaluation and Mitigation Strategy (REMS) program for clozapine to improve safety monitoring of hematologic events. However, the impact of the clozapine REMS program on reporting of hematologic adverse events has not been quantified.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We assessed adverse event reports for agranulocytosis, granulocytopenia, leukopenia, and neutropenia from the FDA Adverse Event Reporting System (FAERS) for a 1-year time period before (October 2014 to September 2015, pre-REMS) and after (October 2015 to September 2016, post-REMS) the implementation of the clozapine REMS program. The AERSMine platform was used to capture historical effect estimates (October 2004 to September 2014). Reporting odds ratios (ROR), proportional reporting ratios (PRR), and corresponding Taylor series 95% confidence intervals (CIs) were calculated for hematologic events with clozapine compared with all other medications using OpenEpi.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Reporting rates for agranulocytosis, granulocytopenia, leukopenia, and neutropenia with clozapine all increased from the pre-REMS to post-REMS time frames, ranging from a 2-fold increase with leukopenia to a 40-fold increase with neutropenia; the composite measure of all hematologic reports had a 12-fold increase. During the post-REMS time frame, the ROR increased by 1691% (111.4, 95% CI 100.6-123.4) compared with the pre-REMS time frame (7.1, 95% CI 5.2-9.6), and the PRR increased by 1280% (83.1, 95% CI 76.8-90.0 vs 6.9, 95% CI 5.1-9.4) for the composite outcome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>We observed significant increases in reports of hematologic adverse events with clozapine after the introduction of the clozapine REMS program. Future research should explore the impact of the less stringent exclusionary and discontinuation criteria on utilization (eg, expanded access) and clinical outcomes (eg, treatment effectiveness and adverse events).<\/jats:p>\n               <\/jats:sec>","DOI":"10.9740\/mhc.2020.05.070","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T20:12:53Z","timestamp":1588882373000},"page":"70-75","source":"Crossref","is-referenced-by-count":13,"title":["Clozapine and hematologic adverse reactions: Impact of the Risk Evaluation and Mitigation Strategy program"],"prefix":"10.9740","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9941-9893","authenticated-orcid":false,"given":"Eric P.","family":"Borrelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8181-5209","authenticated-orcid":false,"given":"Erica Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4180-027X","authenticated-orcid":false,"given":"Aisling R.","family":"Caffrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4719","reference":[{"key":"2020060309422187000_i2168-9709-10-3-70-b01","article-title":"Clozapine [package insert]","year":"2017"},{"issue":"2 Suppl","key":"2020060309422187000_i2168-9709-10-3-70-b02","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"9","key":"2020060309422187000_i2168-9709-10-3-70-b03","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1177\/0706743717720448","article-title":"Guidelines for the pharmacotherapy of schizophrenia in adults","volume":"62","author":"Remington","year":"2017","journal-title":"Can J Psychiatry"},{"issue":"Suppl 1","key":"2020060309422187000_i2168-9709-10-3-70-b04","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.4103\/0019-5545.196972","article-title":"Clinical practice guidelines for management of schizophrenia","volume":"59","author":"Grover","year":"2017","journal-title":"Indian J Psychiatry"},{"issue":"2","key":"2020060309422187000_i2168-9709-10-3-70-b05","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1176\/appi.ps.201700162","article-title":"Addressing barriers to clozapine underutilization: a national effort","volume":"69","author":"Kelly","year":"2018","journal-title":"PS"},{"issue":"2","key":"2020060309422187000_i2168-9709-10-3-70-b06","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1586\/ehm.11.12","article-title":"Clinical presentation and management of drug-induced agranulocytosis","volume":"4","author":"Andr\u00e8s","year":"2011","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"2020060309422187000_i2168-9709-10-3-70-b07","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1038\/ncomms5757","article-title":"Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles","volume":"5","author":"Goldstein","year":"2014","journal-title":"Nat Commun"},{"issue":"2","key":"2020060309422187000_i2168-9709-10-3-70-b08","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.semarthrit.2015.05.009","article-title":"Leukopenia, lymphopenia, and neutropenia in systemic lupus erythematosus: prevalence and clinical impact--A systematic literature review","volume":"45","author":"Carli","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"2020060309422187000_i2168-9709-10-3-70-b09","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1053\/j.seminhematol.2013.06.010","article-title":"Evaluation and management of patients with isolated neutropenia","volume":"50","author":"Newburger","year":"2013","journal-title":"Semin Hematol"},{"issue":"1","key":"2020060309422187000_i2168-9709-10-3-70-b10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s15010-013-0525-9","article-title":"The current spectrum of infection in cancer patients with chemotherapy related neutropenia","volume":"42","author":"Nesher","year":"2014","journal-title":"Infection"},{"issue":"3","key":"2020060309422187000_i2168-9709-10-3-70-b11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3371\/1935-1232.10.3.163","article-title":"Guide to the management of clozapine-related tolerability and safety concerns","volume":"10","author":"Citrome","year":"2016","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"6","key":"2020060309422187000_i2168-9709-10-3-70-b12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/YIC.0b013e32834ab34c","article-title":"Predictors of clozapine discontinuation in patients with schizophrenia","volume":"26","author":"Krivoy","year":"2011","journal-title":"Int Clin Psychopharmacol"},{"issue":"7","key":"2020060309422187000_i2168-9709-10-3-70-b13","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.4088\/JCP.v68n0708","article-title":"Outcome following clozapine discontinuation: a retrospective analysis","volume":"68","author":"Atkinson","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"2020060309422187000_i2168-9709-10-3-70-b14","article-title":"Guidance for industry: format and content of proposed Risk Evaluation and Mitigation Strategies (REMS), REMS assessments, and proposed REMS modifications: draft guidance [Internet]","author":"US Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, US Department of Health and Human Services"},{"key":"2020060309422187000_i2168-9709-10-3-70-b15","article-title":"FDA Drug Safety Communication: FDA modifies monitoring for neutropenia associated with schizophrenia medicine clozapine; approves new shared REMS program for all clozapine medicines [Internet]","year":"2015"},{"key":"2020060309422187000_i2168-9709-10-3-70-b16","article-title":"FDA adverse event reporting system (FAERS) [Internet]","author":"US Food and Drug Administration","year":"2017"},{"issue":"7","key":"2020060309422187000_i2168-9709-10-3-70-b17","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nbt.3623","article-title":"Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data","volume":"34","author":"Sarangdhar","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"8","key":"2020060309422187000_i2168-9709-10-3-70-b18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2020060309422187000_i2168-9709-10-3-70-b19","article-title":"OpenEpi: Open source epidemiologic statistics for public health","author":"Dean","year":"2013"},{"issue":"2","key":"2020060309422187000_i2168-9709-10-3-70-b20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.9740\/mhc.2018.03.063","article-title":"Assessing prescribing practices of clozapine before and after the implementation of an updated risk evaluation and mitigation strategy","volume":"8","author":"Curry","year":"2018","journal-title":"Ment Health Clin [Internet]"},{"issue":"10","key":"2020060309422187000_i2168-9709-10-3-70-b21","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","article-title":"Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias","volume":"30","author":"Pariente","year":"2007","journal-title":"Drug Saf"},{"issue":"3","key":"2020060309422187000_i2168-9709-10-3-70-b22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/pds.4156","article-title":"Incidence and risk estimate of drug-induced agranulocytosis in Hong Kong Chinese. A population-based case-control study","volume":"26","author":"Sing","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"2020060309422187000_i2168-9709-10-3-70-b23","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00228-013-1618-1","article-title":"Drug-induced agranulocytosis in the Berlin case-control surveillance study","volume":"70","author":"Huber","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"2020060309422187000_i2168-9709-10-3-70-b24","article-title":"The Clozapine Risk Evaluation and Mitigation Strategy (REMS) Program M [Internet]","author":"Center for Drug Evaluation and Research"},{"issue":"6","key":"2020060309422187000_i2168-9709-10-3-70-b25","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/phar.1415","article-title":"Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval","volume":"34","author":"McConeghy","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"7","key":"2020060309422187000_i2168-9709-10-3-70-b26","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"2020060309422187000_i2168-9709-10-3-70-b27","unstructured":"US Food and Drug Administration. Questions and answers on FDA's adverse event reporting system (FAERS). Washington: US Department of Health and Human Services;2018."},{"issue":"7","key":"2020060309422187000_i2168-9709-10-3-70-b28","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/14740338.2017.1323867","article-title":"Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"16","author":"Alatawi","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"2020060309422187000_i2168-9709-10-3-70-b29","article-title":"FDA updates pharmacists on clozapine REMS program rollout","author":"Eder","year":"2016","journal-title":"Pharmacy Times"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/10\/3\/70\/2494452\/mhc_2020_05_070.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/10\/3\/70\/2494452\/mhc_2020_05_070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:21:23Z","timestamp":1731687683000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/10\/3\/article-p70.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2020.05.070","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,1]]}}}